The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2016

Filed:

Nov. 28, 2007
Applicants:

Chang-yuil Kang, Seoul, KR;

Hyun-jeong Ko, Seoul, KR;

Jung-mi Lee, Seoul, KR;

Yeon-jeong Kim, Changwon-si, KR;

Inventors:

Chang-Yuil Kang, Seoul, KR;

Hyun-Jeong Ko, Seoul, KR;

Jung-Mi Lee, Seoul, KR;

Yeon-Jeong Kim, Changwon-si, KR;

Assignee:

CELLID CO., LTD., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/164 (2006.01); C12N 5/0786 (2010.01); A61K 39/00 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 31/164 (2013.01); A61K 39/00 (2013.01); C12N 5/0645 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); C12N 2501/999 (2013.01);
Abstract

The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.


Find Patent Forward Citations

Loading…